FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response	: 0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Young Richard A					2. Issuer Name and Ticker or Trading Symbol Omega Therapeutics, Inc. [ OMGA ]									ck all app	,	ng Pers	son(s) to Is		
(Last)	(Fi	rst) (M	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/17/2023										Office below	er (give title		Other (s below)	specify
C/O OMEGA THERAPEUTICS, INC. 20 ACORN PARK DRIVE					4. If <i>I</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
(Street) CAMBRIDGE MA 02140															Form filed by More than One Reporting Person				
(City)	(Si		Zip)	<u> </u>	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									nded to					
		Table	I - Noi	n-Deriva	itive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	3ene	ficial	ly Own	ed 			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da				Execution		Date,	Code (Instr.					3, 4 and Secur		ially Following	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)		Price	Transa	nsaction(s) str. 3 and 4)			(IIISU. 4)	
Common Stock 03/17/2					2023		<b>S</b> <sup>(1)</sup>		10,000	I		\$8	754,118			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins: 3 and 4)		D Si (li	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owners Form: Iy Direct (I or Indire (I) (Instr	Ownership	Beneficial Ownership t (Instr. 4)		
								Date Exercis	able	Expiration Date Tit		Amo or Num of Shar	nber						

## **Explanation of Responses:**

1. The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022.

## Remarks:

/s/ Barbara Chan as Attorneyin-Fact for Richard A. Young, 03/20/2023 Ph.D.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.